Open AccessA randomized trial of 24 versus 48 weeks of peginterferon a-2a plus ribavirin in Egyptian patients with hepatitis C virus genotype 4 and rapid viral response
Author(s) -
Khayat Hre,
Yasser Fouad,
Amin He,
Amal Rizk
Publication year - 2012
Publication title -
tropical gastroenterology
Language(s) - English
Resource type - Journals
eISSN - 2320-5792
pISSN - 0250-636X
DOI - 10.7869/tg.2012.27
Subject(s) - ribavirin , medicine , adverse effect , gastroenterology , hepatitis c virus , viral load , randomized controlled trial , genotype , pegylated interferon , hepatitis c , immunology , virus , biology , biochemistry , gene
Little data is available regarding the 24-week therapy with pegylated interferon and ribavirin in Egyptian patients with hepatitis C virus (HCV) genotype 4 infection. We aimed to investigate the efficacy of 24-week versus 48-week peginterferon alpha-2a plus ribavirin therapy in patients with HCV genotype 4 infection with with rapid virological response.